Capital Analysts LLC
NRIX icon

Capital Analysts LLC’s Nurix Therapeutics NRIX Stock Holding History

Capital Analysts LLC’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$166 Buy
+7
New +$175 ﹤0.01% 1700

Other funds holding NRIX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
General Atlantic
General Atlantic New York $2.48B AUM 19.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Capital Analysts LLC's NRIX Position: Q3 2026 in Review

Capital Analysts LLC opened a new position in Nurix Therapeutics (NRIX) in Q3 2026: 7 shares worth $166. The stake represents ﹤0.01% of the portfolio and ranks #1700 among its holdings.

157 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Capital Analysts LLC held 7 shares of Nurix Therapeutics worth $166 as of Q3 2026.
  • Nurix Therapeutics was a new Capital Analysts LLC position in Q3 2026.
  • Nurix Therapeutics made up ﹤0.01% of Capital Analysts LLC's portfolio in Q3 2026, its #1700 holding.
  • 157 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Capital Analysts LLC's 13F filing for Q3 2026, filed 13 Nov 2026.